South Africa rolls out game-changing HIV shot amid funding shortfalls

South Africa has embarked on a pivotal public health initiative with the rollout of Lenacapavir, a groundbreaking biannual injectable HIV prevention drug, also known as PrEP. This intervention holds the potential to **drastically** reduce HIV infection rates in a nation grappling with the world's largest HIV epidemic, affecting approximately 8 million people and yielding about 160,000 new infections annually. President Cyril Ramaphosa lauded the drug as a 'turning point' in South Africa's national story, emphasizing its significant impact on prevention efforts.

The drug's launch targets 360 health facilities in high-burden districts, aiming to reach those most at risk. A critical demographic is adolescent girls and young women aged 15 to 24, who account for an alarming 1,000 new infections weekly, often due to unequal or transactional relationships. While daily oral PrEP options exist, adherence has proven challenging. Lenacapavir, requiring only two injections per year, offers a far more convenient and potentially effective solution. Dr. Saiqa Mullick, a PrEP specialist, highlights that this 'game-changing technology' could fundamentally alter the trajectory of the epidemic if effectively implemented.

However, the successful deployment of Lenacapavir faces substantial hurdles. Access is currently constrained by reduced U.S. President's Emergency Plan for AIDS Relief (PEPFAR) funding to South Africa, which has undermined existing prevention infrastructure and community programs. Furthermore, the proprietary version of Lenacapavir, manufactured by Gilead, is currently **prohibitive**, costing around $28,000 per person annually in the U.S., making widespread access challenging without significant external support. While the Global Fund has provided enough financing for about 456,000 people over two years, experts stress that this is insufficient to adequately turn the tide on the **epidemic**. Optimistically, generic versions are anticipated by 2027, projected to cost a mere $40 per person per year, with sub-Saharan African countries being a priority for availability. South Africa is also actively pursuing local manufacturing capabilities to enhance regional access and decrease dependency on international supply chains, signaling a long-term strategy for sustained impact and self-sufficiency.